Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
Fádi Fakhouri, Andrew S. Bomback, Gema Ariceta, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole M. Isbel, Moglie Le Quintrec, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Marina Vivarelli, Patrick D. Walker, Dean Wallace, Daniel Zecher, Cedric Francois, Pascal Deschatelets, Li Li, Zhongshen Wang, Lydia Abad‐Franch, Nils Kinnman, Luis López Lázaro, Johan Szamosi, Carla Nester (2025). Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. , 393(22), DOI: https://doi.org/10.1056/nejmoa2501510.
Article18 days agoVALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
Carla Nester, Andrew S. Bomback, Gema Ariceta, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole M. Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Marina Vivarelli, Patrick D. Walker, Dean Wallace, Daniel Zecher, Li Li, Zhongshen Wang, Luis López Lázaro, Johan Szamosi, Fádi Fakhouri (2025). VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN. , 230(4), DOI: https://doi.org/10.1016/j.imbio.2025.153039.
Article18 days ago#3391 Pegcetacoplan treatment appears to halt disease progression in C3G and primary (idiopathic) IC-MPGN patients: results from the phase 3 VALIANT study
Daniel P. Gale, Andrew S. Bomback, Christoph Licht, Carla Nester, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Zhongshen Wang, Johan Szamosi, Dima Decker, Luis Fernando Barba-Gallardo, Fádi Fakhouri (2025). #3391 Pegcetacoplan treatment appears to halt disease progression in C3G and primary (idiopathic) IC-MPGN patients: results from the phase 3 VALIANT study. , 40(Supplement_3), DOI: https://doi.org/10.1093/ndt/gfaf116.0339.
Article18 days ago#288 Pegcetacoplan demonstrates clinically significant responses in C3G and primary (idiopathic) IC-MPGN Patients with or without concomitant immunosuppression in VALIANT
David Kavanagh, Andrew S. Bomback, Gema Ariceta, Antonio Mastrangelo, Carla Nester, Giuseppe Remuzzi, Marina Vivarelli, Zhongshen Wang, Johan Szamosi, Dima Decker, Lenny Gallardo, Fádi Fakhouri (2025). #288 Pegcetacoplan demonstrates clinically significant responses in C3G and primary (idiopathic) IC-MPGN Patients with or without concomitant immunosuppression in VALIANT. , 40(Supplement_3), DOI: https://doi.org/10.1093/ndt/gfaf116.020.
Article18 days agoPegcetacoplan for 52 Weeks Maintains Proteinuria Reduction Regardless of Immunosuppressant Use or Nephrotic-Range Proteinuria at Baseline: VALIANT Subgroup Analysis
Carla Nester, Andrew S. Bomback, María Gema Ariceta Iraola, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole M. Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Marina Vivarelli, Patrick D. Walker, Dean Wallace, Daniel Zecher, Moglie Le Quintrec, Yael Borovitz, Nabil Melhem, Fádi Fakhouri (2025). Pegcetacoplan for 52 Weeks Maintains Proteinuria Reduction Regardless of Immunosuppressant Use or Nephrotic-Range Proteinuria at Baseline: VALIANT Subgroup Analysis. , 36(10S), DOI: https://doi.org/10.1681/asn.20256pz3xtrx.
Article18 days ago